A. Laras et al., INCIDENCE AND CLINICAL-SIGNIFICANCE OF HEPATITIS-B VIRUS PRECORE GENETRANSLATION INITIATION MUTATIONS IN E-ANTIGEN-NEGATIVE PATIENTS, Journal of viral hepatitis, 5(4), 1998, pp. 241-248
Hepatitis Be antigen (HBeAg)-negative chronic hepatitis B (CHB) is ass
ociated with hepatitis B virus (HBV) variants harbouring changes in th
e precore region. Most commonly, a G to A point mutation at nucleotide
1896 (m1896) creates a novel translation stop codon that prevents HBe
Ag production. In the Mediterranean region the m1896 mutation prevails
in greater than 98% of HBeAg-negative CHB patients. In this study the
prevalence of additional mutations in the precore region was investig
ated among patients with chronic HBV infection. Precore sequences were
determined by sequencing serum HBV DNA amplified by polymerase chain
reaction (PCR) with primers flanking the precore/core region. Thirty-o
ne HBeAg-negative and five HBeAg-positive individuals were studied. Al
l HBeAg-negative patients (100%) harboured the m1896 mutation and 20 (
64.5%) also had a G to A mutation at nucleotide 1899 (m1899), Addition
al mutations affecting the translation initiation of the precore gene
were found in seven (22.5%) patients, all with active liver disease, f
ive of whom had episodes of HBV reactivation. HBeAg-positive patients
had no mutations in these positions and neither did any of the five HB
eAg-negative patients with normal levels of liver enzymes, representin
g the healthy carrier state of HBV infection. Serial sample analysis f
rom one patient revealed that the initiation codon mutation developed
following HBeAg seroconversion and the appearance of m1896. During per
iods of high HBV replication, the ratio of mutant to wild-type ATG was
found to increase in parallel with HBV DNA levels. These data show th
at a significant proportion of HBeAg-negative patients who already har
bour the 1896 stop codon mutation may subsequently develop precore tra
nslation initiation mutations, which appear to be associated with enha
nced HBV replication and severe liver disease.